Rocklatan Solution/ Drops
Product Images NDC 70727-529

8 FDA label images from Alcon Laboratories, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rocklatan (NDC 70727-529). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (Cartonlabel)

Carton Label (Cartonlabel)
Packaging label for Rocklatan ophthalmic solution 0.02%/0.005% by Alcon Laboratories, Inc. The label states it is a sterile solution for topical application in the eye, available in a 2.5 mL bottle. Active ingredients include netarsudil mesylate 0.285 mg and latanoprost 0.050 mg per mL. The label includes storage instructions, dosage guidance, barcode, and the NDC 70727-529-25.*
FDA Label Image

Bottle Label (Bottlelabel)

Bottle Label (Bottlelabel)
Label for Rocklatan ophthalmic solution, containing netarsudil and latanoprost 0.02%/0.005%. The sterile solution is 2.5 mL in size and is for topical application in the eye. Labeler is Alcon Laboratories, Inc., Fort Worth, TX. The label includes NDC 70727-529-25 and indicates Rx only status.*
FDA Label Image

Sample Carton Label (Samplecartonlabel)

Sample Carton Label (Samplecartonlabel)
Packaging label for Rocklatan ophthalmic solution 0.02%/0.005% (netarsudil and latanoprost), 2.5 mL sterile eye drops for topical application. Label shows dosage instructions, active and inactive ingredients, storage conditions, and manufacturer Alcon Laboratories, Inc. Marked Sample - Not for Resale with NDC 70727-529-99.*
FDA Label Image

Bottle Label (Samplebottlelabel)

Bottle Label (Samplebottlelabel)
Label of Rocklatan ophthalmic solution 0.02%/0.005% (netarsudil and latanoprost) in a 2.5 mL sterile topical solution. The label includes the NDC 70727-529-99, indicates Rx only, and shows Alcon Laboratories, Inc. as the manufacturer. It notes the product is for topical eye use and includes sample and storage instruction references.*
FDA Label Image

The Chemical Structure Of Netarsudil Mesylate (Image 01)

The Chemical Structure Of Netarsudil Mesylate (Image 01)
Chemical structure diagram of the active ingredient netarsudil, including its molecular components and associated sulfonic acid groups as depicted in the image.*
FDA Label Image

The Chemical Structure Of Latanoprost (Image 02)

The Chemical Structure Of Latanoprost (Image 02)
Chemical structure of netarsudil and latanoprost ophthalmic solution, 0.02%/0.005% active ingredients, showing a detailed molecular diagram with various bonds and functional groups.*
FDA Label Image

Figure 1 (Image 03)

Figure 1 (Image 03)
A line graph comparing the intraocular pressure measurements over time in patients treated with Rocklatan, Netarsudil, and Latanoprost. The x-axis shows time points at day 15, day 43, and day 90, each with three measurement times (8 AM, 10 AM, and 4 PM). The y-axis represents pressure values ranging from 14 to 23 mmHg. Rocklatan shows consistently lower pressure values than either Netarsudil or Latanoprost alone throughout the study period.*
FDA Label Image

Figure 2 (Image 04)

Figure 2 (Image 04)
A line graph comparing intraocular pressure (IOP) measurements at three time points (8AM, 10AM, 4PM) on Days 15, 43, and 90 for Rocklatan, netarsudil, and latanoprost. Data points show Rocklatan consistently having the lowest IOP values, followed by latanoprost, then netarsudil. The graph includes baseline IOP values before treatment initiation for each medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.